A Legal Win for Stem Cell Research, but Case May Not Be Over
By Jocelyn Kaiser,
Science
| 08. 24. 2012
A U.S. appeals court today upheld the legality of federally funded research on human embryonic stem cells (hESCs)—the latest in a string of wins for the National Institutes of Health (NIH) in a 3-year legal battle with groups that for moral reasons want to block the use of these cells. But although hESC researchers can breathe easy for now, the 27-page decision suggests the battle over hESCs may not be quite over.
"It's a clear victory for us. We've very happy with the opinion," says Amy Comstock Rick, an attorney and president of the Coalition for the Advancement of Medical Research, which defends hESC work. However, because the three judges in the appeal of Sherley v. Sebelius issued separate opinions in favor of NIH and used different reasoning, the plaintiffs who filed suit against NIH might have a shot at another review, some legal experts say.
Samuel Casey, an attorney for the plaintiffs, said in a statement: "We are disappointed by the Court of Appeals decision and, given the reasoning in the two concurring opinions, we are evaluating whether and...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...